GlassScriptPhysician profile
Peyton Turner Couper
NPI 1285411363
$1,797.89
in general payments reported to CMS, 2019-2025
27 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $617 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,797.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $264.06 | 2024-2025 | Darzalex, Erleada, Rybrevant |
| Daiichi Sankyo INC. | $263.51 | 2024-2025 | Enhertu, Datroway, Vanflyta |
| Novartis Pharmaceuticals Corporation | $196.51 | 2024-2025 | |
| Abbvie INC. | $176.31 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $128.10 | 2024-2025 | Libtayo |
| Pfizer INC. | $102.57 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $87.58 | 2024-2025 | Tagrisso, Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $64.78 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.49 | 2024-2025 | Fruzaqla, Ninlaro |
| Eisai INC. | $53.08 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $39.67 | 2024-2025 | Orgovyx |
| Celgene Corporation | $38.15 | 2024 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $33.92 | 2024-2025 | Sotyktu, Opdivo |
| Gilead Sciences, INC. | $32.16 | 2024-2025 | Trodelvy |
| Tersera Therapeutics LLC | $28.22 | 2025 | Zoladex |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $24.10 | 2025 | Keytruda |
| Octapharma USA, INC. | $23.89 | 2024 | Octagam Immune Globulin (Human) |
| Genzyme Corporation | $23.67 | 2024 | |
| Stemline Therapeutics INC. | $21.05 | 2025 | Orserdu |
| Syndax Pharmaceuticals, INC. | $20.83 | 2025 | |
| Exelixis INC. | $19.95 | 2024 | Cabometyx |
| Agios Pharmaceuticals, INC. | $19.59 | 2025 | Pyrukynd |
| Janssen Pharmaceuticals, INC | $17.83 | 2025 | Erleada |
| Beone Medicines USA, INC. | $16.25 | 2025 | Brukinsa |
| Geron Corporation | $14.55 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $14.29 | 2024 | Ultomiris |
| Array Biopharma INC | $13.78 | 2024 | Mektovi, Braftovi, Tukysa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peyton Couper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.